Search
vericiguat (Verquvo)
Indications:
- adjunctive treatment for left ventricular systolic dysfunction [1]
Contraindications:
- of no benifit for treatment of left ventricular diastolic dysfunction [2]
Dosage:
- start 2.5 mg, titrate to 10 mg QD
Adverse effects:
- hypotension
- syncope
- anemia
Mechanism of action:
- soluble guanylate cyclase stimulator
- enhances intracellular cyclic GMP pathway
General
soluble guanylate cyclase stimulator
Database Correlations
PUBCHEM correlations
References
- Armstrong PW. Pieske N, Anstrom KJ et al.
Vericiguat in patients with heart failure and reduced ejection fraction.
N Engl J Med 2020; 382:1883-1893. Mar 28; [e-pub].
PMID: 32222134
https://www.nejm.org/doi/10.1056/NEJMoa1915928
- Butler J, Anstrom KJ Armstrong PW
Comparing the benefit of novel therapies across clinical trials:
Insights from the VICTORIA trial.
Circulation 2020 Mar 28; [e-pub]
PMID: 32223438
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047086
- Armstrong PW et al.
Effect of vericiguat vs placebo on quality of life in patients
with heart failure and preserved ejection fraction:
The VITALITY-HFpEF randomized clinical trial.
JAMA 2020 Oct 20; 324:1512.
PMID: 33079152
https://jamanetwork.com/journals/jama/article-abstract/2771900
- FDA Approvals, Highlights, and Summaries: Family Medicine
Medscape - Feb 17, 2022
https://reference.medscape.com/viewarticle/967605